318 related articles for article (PubMed ID: 7949832)
1. Addition of a gonadotropin releasing hormone (GnRH) antagonist and exogenous gonadotropins to unstimulated in vitro fertilization (IVF) cycles: physiologic observations and preliminary experience.
Paulson RJ; Sauer MV; Lobo RA
J Assist Reprod Genet; 1994 Jan; 11(1):28-32. PubMed ID: 7949832
[TBL] [Abstract][Full Text] [Related]
2. The gonadotropin-releasing hormone antagonist (Nal-Glu) acutely blocks the luteinizing hormone surge but allows for resumption of folliculogenesis in normal women.
Ditkoff EC; Cassidenti DL; Paulson RJ; Sauer MV; Paul WL; Rivier J; Yen SS; Lobo RA
Am J Obstet Gynecol; 1991 Dec; 165(6 Pt 1):1811-7. PubMed ID: 1750480
[TBL] [Abstract][Full Text] [Related]
3. Suppression of corpus luteum function by the gonadotropin-releasing hormone antagonist Nal-Glu: effect of the dose and timing of human chorionic gonadotropin administration.
Dubourdieu S; Charbonnel B; Massai MR; Marraoui J; Spitz I; Bouchard P
Fertil Steril; 1991 Sep; 56(3):440-5. PubMed ID: 1894021
[TBL] [Abstract][Full Text] [Related]
4. Effect of administration of a gonadotropin-releasing hormone (GnRH) antagonist (Nal-Glu) during the periovulatory period: the luteinizing hormone surge requires secretion of GnRH.
Dubourdieu S; Charbonnel B; D'Acremont MF; Carreau S; Spitz IM; Bouchard P
J Clin Endocrinol Metab; 1994 Feb; 78(2):343-7. PubMed ID: 8106622
[TBL] [Abstract][Full Text] [Related]
5. Comparison of intermittent and continuous use of a gonadotropin-releasing hormone antagonist (Nal-Glu) in in vitro fertilization cycles: a preliminary report.
Cassidenti DL; Sauer MV; Paulson RJ; Ditkoff EC; Rivier J; Yen SS; Lobo RA
Am J Obstet Gynecol; 1991 Dec; 165(6 Pt 1):1806-10. PubMed ID: 1750479
[TBL] [Abstract][Full Text] [Related]
6. Differential regulation of luteinizing hormone, follicle-stimulating hormone, and free alpha-subunit secretion from the gonadotrope by gonadotropin-releasing hormone (GnRH): evidence from the use of two GnRH antagonists.
Hall JE; Whitcomb RW; Rivier JE; Vale WW; Crowley WF
J Clin Endocrinol Metab; 1990 Feb; 70(2):328-35. PubMed ID: 2105329
[TBL] [Abstract][Full Text] [Related]
7. The synergistic effects of clomiphene citrate and human menopausal gonadotrophin in the folliculogenesis of stimulated cycles as assessed by the gonadotrophin-releasing hormone antagonist Nal-Glu.
Cassidenti DL; Paulson RJ; Lobo RA; Sauer MV
Hum Reprod; 1992 Mar; 7(3):344-8. PubMed ID: 1587939
[TBL] [Abstract][Full Text] [Related]
8. Effect of gonadotrophin-releasing hormone (GnRH) antagonist during the LH surge in normal women and during controlled ovarian hyperstimulation.
Christin-Maitre S; Olivennes F; Dubourdieu S; Chabbert-Buffet N; Charbonnel B; Frydman R; Bouchard P
Clin Endocrinol (Oxf); 2000 Jun; 52(6):721-6. PubMed ID: 10848876
[TBL] [Abstract][Full Text] [Related]
9. Nonsupplemented luteal phase characteristics after the administration of recombinant human chorionic gonadotropin, recombinant luteinizing hormone, or gonadotropin-releasing hormone (GnRH) agonist to induce final oocyte maturation in in vitro fertilization patients after ovarian stimulation with recombinant follicle-stimulating hormone and GnRH antagonist cotreatment.
Beckers NG; Macklon NS; Eijkemans MJ; Ludwig M; Felberbaum RE; Diedrich K; Bustion S; Loumaye E; Fauser BC
J Clin Endocrinol Metab; 2003 Sep; 88(9):4186-92. PubMed ID: 12970285
[TBL] [Abstract][Full Text] [Related]
10. Prevention of premature luteinizing hormone and progesterone rise with a gonadotropin-releasing hormone antagonist, Nal-Glu, in controlled ovarian hyperstimulation.
Frydman R; Cornel C; de Ziegler D; Taieb J; Spitz IM; Bouchard P
Fertil Steril; 1991 Nov; 56(5):923-7. PubMed ID: 1936328
[TBL] [Abstract][Full Text] [Related]
11. Spontaneous luteinizing hormone surges can be reliably prevented by the timely administration of a gonadotrophin releasing hormone antagonist (Nal-Glu) during the late follicular phase.
Frydman R; Cornel C; de Ziegler D; Taieb J; Spitz IM; Bouchard P
Hum Reprod; 1992 Aug; 7(7):930-3. PubMed ID: 1430131
[TBL] [Abstract][Full Text] [Related]
12. Follicular arrest during the midfollicular phase of the menstrual cycle: a gonadotropin-releasing hormone antagonist imposed follicular-follicular transition.
Kettel LM; Roseff SJ; Chiu TC; Bangah ML; Vale W; Rivier J; Burger HG; Yen SS
J Clin Endocrinol Metab; 1991 Sep; 73(3):644-9. PubMed ID: 1908486
[TBL] [Abstract][Full Text] [Related]
13. The utility of a midcycle follicle-stimulating hormone boost in addition to human chorionic gonadotropin for timing of follicle aspiration in unstimulated in vitro fertilization cycles.
Lindheim SR; Sauer MV; Francis MM; Macaso T; Lobo R; Paulson RJ
Gynecol Obstet Invest; 1997; 43(2):76-8. PubMed ID: 9067710
[TBL] [Abstract][Full Text] [Related]
14. Gonadotropin requirements of the developing follicle.
Thompson KA; LaPolt PS; River J; Henderson G; Dahl KD; Meldrum DR
Fertil Steril; 1995 Feb; 63(2):273-6. PubMed ID: 7843430
[TBL] [Abstract][Full Text] [Related]
15. Gonadotropin-releasing hormone antagonist versus agonist administration in women undergoing controlled ovarian hyperstimulation: cycle performance and in vitro steroidogenesis of granulosa-lutein cells.
Minaretzis D; Alper MM; Oskowitz SP; Lobel SM; Mortola JF; Pavlou SN
Am J Obstet Gynecol; 1995 May; 172(5):1518-25. PubMed ID: 7755066
[TBL] [Abstract][Full Text] [Related]
16. Variable tolerance of the developing follicle and corpus luteum to gonadotropin-releasing hormone antagonist-induced gonadotropin withdrawal in the human.
Hall JE; Bhatta N; Adams JM; Rivier JE; Vale WW; Crowley WF
J Clin Endocrinol Metab; 1991 May; 72(5):993-1000. PubMed ID: 1902489
[TBL] [Abstract][Full Text] [Related]
17. Endogenous LH surge versus hCG as ovulation trigger after low-dose highly purified FSH in IUI: a comparison of 761 cycles.
Romeu A; Monzó A; Peiró T; Diez E; Peinado JA; Quintero LA
J Assist Reprod Genet; 1997 Oct; 14(9):518-24. PubMed ID: 9401870
[TBL] [Abstract][Full Text] [Related]
18. Recombinant luteinizing hormone supplementation to recombinant follicle-stimulating hormone induced ovarian hyperstimulation in the GnRH-antagonist multiple-dose protocol.
Griesinger G; Schultze-Mosgau A; Dafopoulos K; Schroeder A; Schroer A; von Otte S; Hornung D; Diedrich K; Felberbaum R
Hum Reprod; 2005 May; 20(5):1200-6. PubMed ID: 15665010
[TBL] [Abstract][Full Text] [Related]
19. Revival of the natural cycles in in-vitro fertilization with the use of a new gonadotrophin-releasing hormone antagonist (Cetrorelix): a pilot study with minimal stimulation.
Rongières-Bertrand C; Olivennes F; Righini C; Fanchin R; Taïeb J; Hamamah S; Bouchard P; Frydman R
Hum Reprod; 1999 Mar; 14(3):683-8. PubMed ID: 10221695
[TBL] [Abstract][Full Text] [Related]
20. Basal serum progesterone and history of elevated progesterone on the day of hCG administration are significant predictors of late follicular progesterone elevation in GnRH antagonist IVF cycles.
Venetis CA; Kolibianakis EM; Bosdou JK; Lainas GT; Sfontouris IA; Tarlatzis BC; Lainas TG
Hum Reprod; 2016 Aug; 31(8):1859-65. PubMed ID: 27301360
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
